As Greenphire’s Head of Corporate Development, Abran leads the inorganic strategy for the company, including assessing growth and innovation opportunities in all healthcare markets, establishing strategic relationships with highly complimentary organizations and executing on Mergers & Acquisitions (M&A).
Abran has over twenty years of professional healthcare experience that spans most end-market segments including commercial and clinical pharma, payer, provider, consumer and government. Prior to joining Greenphire, Abran led Corporate Development for HMS (Nasdaq: HMSY) and was a senior Corporate Development Officer at IMS Health during the take-private by TPG Capital (now NYSE: IQV). In those roles, and through M&A, Abran drove transformation and entry into new business segments such as clinical trial optimization, payer and provider services, social media monitoring, mobile health, health economics and outcomes research services, real-world evidence solutions, government services, genomics, consumer health, population health and patient engagement. Abran also helped lead IMS Health’s $1.3B IPO in 2014. Abran was the founder and CEO of two data-driven healthcare software startups and previously worked as a healthcare investment banker for Bear, Stearns & Co. and held various operational roles at Pfizer and Johnson & Johnson, both in the United States and in Europe.
Abran earned a Bachelor of Science in International Business and Finance from Northeastern University in Boston, MA and an MBA from IESE Business School in Barcelona, Spain. Abran resides in Connecticut with his wife and three daughters and is a winter sports enthusiast.
